The new Proteomics Resource Core at the NYU School of Medicine is committed to provide the biomedical research community access to state of the art mass spectrometric technology to facilitate their research and improve the scientific infrastructure. We are therefore requesting funds for an Orbitrap Elite mass spectrometer with Electron Transfer Dissociation (ETD) from Thermo Fisher Scientific to enable high throughput proteomic studies for the identification and quantification of proteins in complex mixtures, characterization of protein complexes, mapping of post translational modifications, as well as in depth structural characterization of proteins and peptides. We have assembled a group of multidisciplinary users at NYU and at Hunter College (City University of New York) whose work on mechanisms of cancer progression through over- or inactivation of the ubiquitin pathway, stem cell regulation, DNA replication control, transcription factor regulation, chromatin regulation, bladder urothelial formation, as well as drug development using natural sources (venoms) will be impossible without an in-house state of the art mass spectrometer.
Proteins are key regulators of biological processes. To fully understand their role in human diseases and establish targets for therapies, mass spectrometry has evolved as a key technology to characterize proteins in the healthy and diseased condition. The here proposed mass spectrometer is a state of the art instrument that has unsurpassed protein sequencing speed and sensitivity that will enable NIH funded researches to characterize and quantitate proteins in biological contexts to increase our understanding of cellular function on a molecular level and ultimately aid in curing human diseases and improve quality of life.
